Stefanie Schatz
Overview
Explore the profile of Stefanie Schatz including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
15
Citations
293
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Falk M, Schatz S, Reich F, Schmidt S, Galster M, Tiemann M, et al.
Curr Oncol
. 2023 Oct;
30(10):8865-8871.
PMID: 37887540
Osimertinib has become the preferred first-line therapy for epidermal growth factor receptor ( mutation-positive metastatic non-small cell lung cancer (NSCLC) in recent years. Originally, it was approved for second-line treatment...
2.
Schatz S, Willnow L, Winkels M, Rosengarten J, Theek B, Johnston I, et al.
Antibodies (Basel)
. 2023 Sep;
12(3).
PMID: 37753971
Efficient induction of target-specific antibodies can be elicited upon immunization with highly immunogenic virus-like particles (VLPs) decorated with desired membrane-anchored target antigens (Ags). However, for example, for diagnostic purposes, monoclonal...
3.
Willing E, Vollbrecht C, Vossing C, Weist P, Schallenberg S, Herbst J, et al.
Cancers (Basel)
. 2023 Jul;
15(13).
PMID: 37444554
The worldwide approval of the combination maintenance therapy of olaparib and bevacizumab in advanced high-grade serous ovarian cancer requires complex molecular diagnostic assays that are sufficiently robust for the routine...
4.
Schatz S, van Dijk F, Dubiel A, Cantz T, Eggenschwiler R, Stitz J
Methods Mol Biol
. 2023 Jul;
2681:361-371.
PMID: 37405658
Suspension cells derived from human embryonic kidney cells (HEK 293) are attractive cell lines for retroviral vector production in gene therapeutic development studies and applications. The low-affinity nerve growth factor...
5.
van Heuvel Y, Schatz S, Hein M, Dogra T, Kazenmaier D, Tschorn N, et al.
Front Bioeng Biotechnol
. 2023 Apr;
11:1076524.
PMID: 37082212
To date, the establishment of high-titer stable viral packaging cells (VPCs) at large scale for gene therapeutic applications is very time- and cost-intensive. Here we report the establishment of three...
6.
Falk M, Willing E, Schmidt S, Schatz S, Galster M, Tiemann M, et al.
Curr Oncol
. 2023 Feb;
30(2):1692-1698.
PMID: 36826091
HER2-targeted therapy is currently the subject of several studies in lung cancer and other solid tumors using either tyrosine kinase inhibitors (TKI) or targeted-antibody-drug conjugates. We describe a 61-year-old female...
7.
Rosengarten J, Schatz S, Stitz J
J Vis Exp
. 2022 Feb;
(180).
PMID: 35225285
The virus-like particle (VLP) capture assay is an immunoprecipitation method, commonly known as a 'pull-down assay' used to purify and isolate antigen-displaying VLPs. Surface antigen-specific antibodies are coupled to, and...
8.
Clausen S, Falk M, Oesterling F, Fehr A, Stang A, Boecker W, et al.
Anticancer Res
. 2022 Feb;
42(3):1455-1463.
PMID: 35220239
Background/aim: Polymorphous adenocarcinoma (PAC) is a low-grade salivary gland malignancy in contrast to variants with papillary (PAP) or cribriform (CASG) architecture and confers the second most common malignancy of minor...
9.
van Heuvel Y, Schatz S, Rosengarten J, Stitz J
Toxins (Basel)
. 2022 Feb;
14(2).
PMID: 35202165
Different mechanisms mediate the toxicity of RNA. Genomic retroviral mRNA hijacks infected host cell factors to enable virus replication. The viral genomic RNA of the human immunodeficiency virus (HIV) encompasses...
10.
Rosengarten J, Schatz S, Wolf T, Barbe S, Stitz J
Virology
. 2022 Feb;
568:41-48.
PMID: 35101772
The sequence diversity of HIV-1 is the biggest hurdle for the design of a prophylactic vaccine. Mosaic (Mos) antigens consisting of synthetically shuffled epitopes from various HIV-1 strains are currently...